FB231 |
Catalog No.GC81698
One-Click Copy Product Info
|
FB231 is a Parkin activator.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2166045-37-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, FB231 activates Parkin and enhances Parkin-mediated mitophagy induced by low-dose Oligomycin /Antimycin (O/A) (EC50 = 0.67 μM)[1]. FB231 (0.3125-20 μM, 6-24 h) reduces the threshold of O/A-induced mitophagy in YFP-Parkin/mt-Keima-expressing HeLa cells and SH-SY5Y cells with endogenous Parkin[1]. FB231 effectively chelates Fe2+ with an EC50 of 23.2 μM[1]. FB231 (6 h) increases mitochondrial oxygen consumption rate (OCR) and reduces cell sensitivity to the complex V inhibitor Oligomycin in WT HeLa cells[1]. FB231 (3.125-20μM, 24 h) reduces cell viability in HeLa and SH-SY5Y cells[1]. FB231 (10 μM, 16 h) induces the expression of ISR markers ATF3, ATF4, and IFRD1 in WT HeLa, YFP-Parkin HeLa, and PINK1-knockout HeLa cells [1]. FB231 (40 μM) stabilizes the HECT domain E3 ligase HERC4 and destabilizes the iron-responsive protein IREB2[1].
References:
[1]. Rosencrans WM, et al. Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress. Sci Adv. 2025 Aug 29;11(35):eady0240.
| Cas No. | 2166045-37-8 | SDF | |
| Formula | C24H21N5O2 | M.Wt | 411.46 |
| Solubility | DMSO: 100 mg/mL (243.04 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4304 mL | 12.1518 mL | 24.3037 mL |
| 5 mM | 486.1 μL | 2.4304 mL | 4.8607 mL |
| 10 mM | 243 μL | 1.2152 mL | 2.4304 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)